Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Bismuth Subsalicylate on Gut Microbiome in Healthy Adults
NCT05930197Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Aug 2023
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of bismuth subsalicylate in diarrhea, sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoint: Effect of BSS on the Human Gut Microbiome at 28 days. Started Aug 2023; status: completed.
02
Drugs
bismuth subsalicylate
03
Conditions
diarrhea
Beyond the preview
Go deeper on NCT05930197.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05930197.